Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.
OBJECTIVE
To investigate positron emission tomography (PET) with (fluorine-18)-2-deoxyglucose (FDG) for detecting recurrent ovarian carcinoma.


METHODS
Wholebody FDG-PET scanning was performed on five patients before surgical exploration. All five patients were suspected of having recurrence based upon clinical findings and underwent surgery after scanning.


RESULTS
In all five patients, PET images demonstrated increased FDG uptake in a distribution that correlated with surgical-pathologic findings (100%); computer tomography can detect 60% of such patients with malignant disease. Two cases with unexplained elevated serum CA-125 had lesions localized by PET.


CONCLUSIONS
Recurrence of ovarian carcinoma was clearly imaged with FDG-PET and was confirmed by surgical pathology. FDG-PET might be a fairly effective tool for detecting recurrent ovarian carcinoma.
Yuan
C C
CC
Department of Obstetrics and Gynecology, Veterans General Hospital-Taipei, School of Medicine, National Yang-Ming University, Taiwan. ccyuan@vghtpe.gov.tw
Liu
R S
RS
Wang
P H
PH
Ng
H T
HT
Yeh
S H
SH
D018394:CA-125 Antigen / Q000097:blood; D003847:Deoxyglucose; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D018394:CA-125 Antigen; D005462:Fluorine Radioisotopes; D003847:Deoxyglucose